175 related articles for article (PubMed ID: 12352409)
1. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
Rigaud J; Tiguert R; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
J Urol; 2002 Oct; 168(4 Pt 1):1423-6. PubMed ID: 12352409
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
Hori S; Jabbar T; Kachroo N; Vasconcelos JC; Robson CN; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2011 Feb; 137(2):235-41. PubMed ID: 20390426
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
7. Is there a favorable subset of patients with prostate cancer who develop oligometastases?
Singh D; Yi WS; Brasacchio RA; Muhs AG; Smudzin T; Williams JP; Messing E; Okunieff P
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):3-10. PubMed ID: 14697414
[TBL] [Abstract][Full Text] [Related]
8. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
9. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
10. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.
Yamaguchi Y; Hayashi Y; Ishizuya Y; Takeda K; Nakai Y; Arai Y; Nakayama M; Kakimoto K; Nishimura K
Jpn J Clin Oncol; 2015 Feb; 45(2):197-201. PubMed ID: 25381383
[TBL] [Abstract][Full Text] [Related]
11. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ
Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893
[TBL] [Abstract][Full Text] [Related]
12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
Afriansyah A; Hamid ARA; Mochtar CA; Umbas R
Int J Urol; 2019 Jan; 26(1):83-89. PubMed ID: 30269369
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
15. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
17. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
18. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment.
Bantis A; Zissimopoulos A; Kalaitzis C; Giannakopoulos S; Sountoulides P; Parmenopoulou V; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2008; 11(1):21-5. PubMed ID: 18392222
[TBL] [Abstract][Full Text] [Related]
19. [Bone scintigraphy and rhenium radioisotope management in the course of metastatic prostatic cancer].
Ostwald E; Sabri O; Cremerius U; Jakse G; Büll U
Nuklearmedizin; 1999; 38(7):302-5. PubMed ID: 10599071
[TBL] [Abstract][Full Text] [Related]
20. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]